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Vpr, an accessory protein of HIV, is known to affect viral replication as well as cell growth, differentiation, and apoptosis
in vitro. To investigate its pathogenicity in vivo, we have produced mice transgenic for the HIV-1 vpr gene with the CD4
enhancer/promoter. Interestingly, apoptotic death of T lymphocytes was enhanced in those mice, causing marked reduction
of T cells in lymphatic organs and peripheral blood. Involvement of Bcl-x, Bax, and Caspase-1, but not of the Fas–Fas ligand
system, was suggested in the apoptotic processes. These observations suggest that Vpr is involved in the pathogenesis of
T cell depletion in HIV-infected people. © 2001 Academic Press
g
a
t
p
(
a
i
t
e
1
a
C
1
g
t
t
(
i
c
c
A
t
g
w
t
f
v
H
r
rINTRODUCTION
The vpr gene encodes a 14-kDa basic protein and is
highly conserved among isolates of HIV-1, HIV-2, and SIV
(Levy et al., 1995b). Although Vpr is a nonstructural pro-
tein, large amounts of Vpr are incorporated in HIV virions
by interacting with the p6 domain of the p55gag precursor
rotein (Paxton et al., 1993). Vpr is also secreted from the
nfected cells and significant levels of this protein are
etected in the serum of AIDS patients (Levy et al., 1994).
The investigation using recombinant proviral clones
lacking a functional vpr gene suggested that Vpr is nec-
essary for productive HIV-1 replication in primary mono-
cytes (Westervelt et al., 1992), although relatively little
effect on the replication was detected in transformed T
lymphocytes (Ogawa et al., 1989). Enhancing effects on
iral replication were also observed by adding Vpr exog-
nously to transformed cells or peripheral blood mono-
uclear cells (Levy et al., 1995a). The mechanisms of Vpr
ction in viral replication have not been elucidated com-
letely; however, several reports suggest a crucial role in
arly stages of viral infection. Heinzinger et al. suggested
hat Vpr is involved in transporting viral preintegration
omplexes from the cytoplasm to the nucleus and in
stablishing HIV-1 infection in nondividing cells, most
mportantly in macrophages (Heinzinger et al., 1994). It
as also shown that Vpr enhances long terminal repeat
LTR)-directed transcription of viral genes through inter-
ction with cellular transcription factors such as Sp1 and
1 To whom correspondence and reprint requests should be ad-
ressed at the Center for Experimental Medicine, Institute of Medicalb
s
cience, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108-8639,
apan. Fax: 181-3-5449-5430. E-mail: iwakura@ims.u-tokyo.ac.jp.
181lucocorticoid receptor (GR) (Refaeli et al., 1995; Wang et
l., 1995). Vpr trans-activation through Sp1 is crucial for
he immediate-early transcription of HIV-1, when other
ositive regulators such as NF-kB are limited or inactive
Wang et al., 1995).
It was also reported that Vpr affects cellular growth
nd differentiation; Vpr induces myogenic differentiation
n rhabdomyosarcoma cells by causing enlargement of
he cells, suppression of proliferation, and high-level
xpression of a muscle-specific protein (Levy et al.,
993). Furthermore, vpr-transfected cells were arrested
t the G2 phase of the cell cycle due to inactivation of
dc2 kinase (He et al., 1995; Jowett et al., 1995; Re et al.,
995; Rogel et al., 1995). Since expression of the viral
enome is optimal in the G2 phase, it was suggested
hat Vpr increases virus production by delaying cells at
he point of the cell cycle at which the LTR is most active
Goh et al., 1998). Recently, it was reported that Vpr can
nduce apoptosis in cells of established lines and in
ultured peripheral blood lymphocytes (PBL) following
ell cycle arrest (Stewart et al., 1997). On the other hand,
yyavoo et al. reported that Vpr modulates T cell recep-
or-triggered apoptosis in a manner similar to that of
lucocorticoid (GC), and this Vpr-induced suppression
as inhibited by a GC antagonist, RU486, suggesting
hat Vpr may mimic some functional aspects of GC by
orming a complex with GR and regulating expression of
iral as well as cellular genes (Ayyavoo et al., 1997).
owever, the mechanisms of Vpr-induced cell cycle ar-
est and apoptosis, and the relation between them, still
emain largely unknown.
The roles of Vpr in the pathogenesis of AIDS have
een investigated using the SIV and rhesus monkey
ystem. Lang et al. and Hoch et al. showed that the viral
0042-6822/01 $35.00
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182 YASUDA ET AL.burden was low in monkeys infected with vpr-mutant SIV
and the disease progression delayed, although those
vpr-deficient SIV could finally induce AIDS in rhesus
monkeys (Hoch et al., 1995; Lang et al., 1993). In contrast,
Gibbs et al. did not observe any effects of vpr mutation
on the progression of the disease in rhesus monkeys,
although double mutation with vpx, a gene closely re-
lated to vpr, caused severe attenuation of disease pro-
gression (Gibbs et al., 1995). Thus, pathogenic roles of
Vpr in the development of AIDS remained controversial.
In this study, in order to examine the pathological
effects of Vpr on an animal, we have produced trans-
genic (Tg) mice expressing the HIV-1 vpr gene under the
control of the mouse CD4 promoter/enhancer (Vpr-Tg
mice). We found in these Tg mice that T lymphocytes
both in the thymus and in the periphery were decreased
due to enhanced apoptosis. Furthermore, data indicated
that this Vpr-mediated thymocyte apoptosis was induced
by a Fas-independent pathway, and involvement of cel-
lular apoptosis-related genes such as bcl-x, bax, and
caspase-1 was suggested. We will discuss possible in-
volvement of Vpr in CD41 T cell depletion in AIDS pa-
tients.
RESULTS
Production of mice transgenic for the HIV-1 vpr gene
A transgene consisting of the mouse CD4 enhancer/
promoter, the HIV-1 NL4-3 vpr, and a defective human
rowth hormone gene containing the introns and the
oly(A) signal was constructed (Fig. 1A). The DNA was
njected into 1170 fertilized mouse ova, and 28 mice that
arried the transgene were obtained.
The vpr mRNA expression from the transgene of the F1
ice was examined by Northern blot hybridization anal-
sis (Fig. 1B). Although the size of vpr mRNA was ex-
ected to be 1.1 kb, transcriptional products were de-
ected at the size range of 1.1 to 1.9 kb, probably because
f the alternative splicing forms in the human growth
ormone gene. The expression level was high in the
hymus, but that in the spleen and lymph nodes was only
pproximately 1/100 and 1/50 that in the thymus, respec-
ively. Mice from transgenic lines, T3 and T5, showed the
ighest expression levels among 10 lines that we exam-
ned, while vpr expression in the other lines was too
eak to detect by Northern analysis and no phenotypes
ere observed in mice from these lines. Therefore, we
stablished these two lines, T3 and T5, for further anal-
sis. Five copies of the transgene was detected in T3-
ine heterozygous mice and seven copies in T5-line mice.
hese two lines showed very similar phenotypes with
espect to the tissue specificity of the transgene expres-
ion, the thymic anatomy, and the peripheral T cell con-
ent. Thus, we mainly analyzed mice from line T5 in detail
n the following studies.
Vpr protein expression in the T5 line was also exam-
r
tned by Western blotting. As shown in Fig. 1C, Vpr protein
as detected in all lymphatic organs examined. The
xpression level was highest in the thymus, consistent
ith the results from Northern analyses. Expression level
n the transgenic thymus was approximately 10-fold
ower than that in Jurkat cells infected with HIV-1 NL4-3,
uggesting that the effects observed in vpr-transgenic
ice are not due to nonphysiological overexpression of
pr.
ymphocyte population in Vpr-Tg mice
Histological studies revealed thymic atrophy in these
pr-Tg mice, while the spleen and lymph nodes ap-
eared normal (Fig. 2). The average weights of the thy-
uses from heterozygous and homozygous Vpr-Tg mice
ere only 60 and 40% of those from non-Tg littermates,
FIG. 1. Production of HIV-1 vpr Tg mice. (A) The vpr transgene
construct. The HIV-1 vpr gene was placed downstream of the mouse
CD4 (mCD4) enhancer/promoter and followed by a defective human
growth hormone gene containing the polyadenylation signal (DhGH).
(B) Transgene expression in lymphatic organs. Northern blot hybridiza-
tion analysis was performed with 1.7 mg of poly(A)1 RNA prepared from
he thymus, spleen, or lymph nodes (L.N.) of T3- and T5-line Tg mice.
he positions expected for the vpr and b-actin mRNAs are indicated on
the right. (C) Vpr expression in lymphatic organs. Western blotting was
performed with 250 mg of cell lysates from the thymus (Thy), lymph
odes (LN), or spleen (Sp) of T5-homozygous mice or 50 mg of lysate
from Jurkat cells infected with NL4-3. M, mock-infected Jurkat cells. 2d
and 6d, lysates were prepared from cells at 2 and 6 days postinfection.espectively, indicating that thymocytes were reduced in
hese mice.
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183T CELL APOPTOSIS IN MICE TRANSGENIC FOR HIV-1 vprThe cell population was analyzed by a fluorescence-
activated cell sorter (FACS). In the thymus of Vpr-Tg mice,
the proportion of CD41CD81 cells decreased slightly and
FIG. 3. Depletion of T lymphocytes in Vpr-Tg mice. Lymphocyte popul
anti-mouse CD4 and FITC-conjugated anti-mouse CD8. (B) Cells prepa
FIG. 2. Involution of the thymus in Vpr-Tg mice. (A) Macroscopic app
eterozygous Tg mouse (center), and non-Tg mouse (left). Note that Tg t
eight. Animals used in this experiment were females at 8 weeks of
pr/vpr, Vpr homozygous Tg mice. *P , 0.005; **P , 0.001.labeled with PE-conjugated anti-mouse B220 and FITC-conjugated anti-mouse
FITC-conjugated anti-mouse CD8. Female mice at the age of 9 weeks were usthose of CD42CD82 cells and CD42CD81 cells in-
reased (Fig. 3A). The CD41CD82 population also de-
creased in this organ.
as analyzed by FACS. (A) Thymocytes were labeld with PE-conjugated
m peripheral lymphatic organs (spleen, lymph nodes, and PBL) were
e of the thymus at 13 weeks of age. vpr-homozygous Tg mouse (right),
es are involuted. (B) Thymus weight of Vpr-Tg mice normalized by body
d controls were non-Tg littermates. vpr/2, Vpr heterozygous Tg mice;ation w
red froearanc
hymusCD3. (C) Cells were labeled with PE-conjugated anti-mouse CD4 and
ed. These results are representative of two independent experiments.
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185T CELL APOPTOSIS IN MICE TRANSGENIC FOR HIV-1 vprAlthough the spleen and lymph node weights were
normal, the T cell content in these organs drastically
decreased in Vpr-Tg mice (Fig. 3B). In the spleen, the T
cell proportion decreased from 36.4 to 17.2% (non-Tg vs
homozygous Vpr-Tg) and in the lymph nodes from 85.6 to
27.3%. The T cell proportion also decreased in PBL: 57.7%
in non-Tg mice, 25.0% in heterozygous Vpr-Tg mice, and
10.4% in homozygous mice. In these Tg mice, both CD4
and CD8 single-positive T cell proportions decreased in
peripheral lymphatic organs (Fig. 3C). For example, CD4
single-positive T cell populations in PBL decreased from
40.8 to 4.9% in homozygous Vpr-Tg mice and CD8 single-
positive cells also decreased from 13.9 to 1.9%. Instead,
the double-negative population, likely representing B
cells, increased in these Tg mice. Total cell number of
lymphocytes was unchanged in the spleen and lymph
nodes, but decreased in the thymus and peripheral blood
in Tg mice [thymus, (5.3 6 2.2) 3 107 cells (non-Tg) vs
1.5 6 0.2) 3 107 cells (heterozygous Vpr-Tg); PBL, (2.3 6
.5) 3 103 cells/ml (non-Tg) vs (6.1 6 1.6) 3 102 cells/ml
homozygous Vpr-Tg)]. Although the proportions of
D42CD82 cells and CD42CD81 cells in the thymus of
Vpr-Tg mice seemingly increased in Fig. 3A, cell number
in these populations actually decreased. Based on this
lymphocyte number and the T cell content in PBL, the T
cell number in PBL was calculated as (1.3 6 0.3) 3 103
cells/ml in non-Tg mice and (6.3 6 1.7) 3 101 cells/ml in
homozygous Vpr-Tg mice. These observations indicate
that absolute T cell number decreased in Vpr-Tg mice.
Thymocyte apoptosis in Vpr-Tg mice
Previously, it was reported that expression of HIV-1 Vpr
causes G2 arrest of the cell cycle (He et al., 1995; Jowett
et al., 1995; Re et al., 1995; Rogel et al., 1995). Therefore,
we examined the possibility that the cell cycle arrest is
involved in the T cell depletion observed in Vpr-Tg mice.
In order to determine the cell population in each stage of
the cell cycle, thymocytes were labeled with propidium
iodide (PI) and the DNA content was analyzed by FACS
(Fig. 4A). The proportion of cells in the G2/M phase was
unchanged in the Tg thymus compared with that from
non-Tg mice (Fig. 4B), while a decrease of cells in G0/G1
phase and increase of cells in S phase were observed.
Interestingly, this cell cycle analysis revealed significant
increase of thymocyte population in apoptosis (2.1% vs
9.6%).
To confirm the increase of apoptotic cells in the Vpr-Tg
thymus, thymocytes were stained with Annexin V, which
specifically binds phosphatidylserine, an integral com-
ponent of the inner plasma membrane. It is known that
membrane integrity is lost and phosphatidylserine is
exposed during the initial steps of apoptosis, allowing
Annexin V to bind to these cells (Fadok et al., 1992). In
this assay, PI stains only the cells whose membrane
integrity is severely disrupted. Thus, cells stained withAnnexin V but not with PI are considered to represent
cells in apoptosis at the initial stage and those stained
with both Annexin V and PI to represent late stage
apoptotic cells and necrotic cells. The percentage of
early stage apoptotic thymocytes was shown to be 19.0%
in vpr-homozygous mice and 8.4% in non-Tg mice (Fig.
5A). Thus, these data indicated that apoptosis of thymo-
cytes was facilitated in Vpr-Tg mice. Apoptotic cell pop-
ulation was also increased in peripheral lymphocytes
FIG. 4. Increase of apoptotic cell population in thymocytes of Vpr-Tg
mice revealed by cell cycle analysis. Thymocytes were prepared from
non-Tg and homozygous Vpr-Tg (vpr/vpr) mice, and the proportion of
cells in each cell cycle and in apoptosis was analyzed by FACS after
staining with PI (A). The averages and the SD of six independent
experiments are shown in (B). Student’s t test was used for statistical
evaluation of the results. *P , 0.05; **P , 0.01.from Vpr-Tg mice (Figs. 5B and 5C).
Apoptotic cell death of thymocytes was confirmed his-
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186 YASUDA ET AL.tologically. Thymocytes were greatly reduced in the
Vpr-Tg thymus, especially in the cortical area (Figs. 6A
and 6B). Further analysis using the TUNEL method,
which detects DNA lesions, showed that the number of
apoptotic cells was significantly increased in the Vpr-Tg
thymus (Figs. 6C and 6D), consistent with the results
obtained from FACS analyses.
Viability of Vpr-Tg thymocytes in vitro
Since enhancement of thymocyte apoptosis was ob-
served in vivo, viability of Vpr-Tg thymocytes was exam-
ined in vitro by trypan blue dye exclusion test and MTT
assay. Although the MTT assay is a method to estimate
the cell viability by measuring the metabolic activity of
the cells, sometimes it may not give an accurate survival
rate. Therefore, in order to provide more accurate repre-
sentation of percentage survival, we also used the trypan
blue staining method in this study. When thymocytes
FIG. 5. Apoptotic cell death of Vpr-Tg lymphocytes detected by
Annexin V staining. Thymocytes (A), lymph node cells (B), or peripheral
blood lymphocytes (C) from non-Tg and Vpr-Tg mice were stained with
Annexin V and PI. These results are representative of three indepen-
dent experiments.from non-Tg and Vpr-Tg mice were cultured in vitro,
thymocytes from Vpr-Tg mice died significantly faster
s
gthan those of non-Tg mice (Figs. 7A and 7B). These
results indicate that the observed thymocyte apoptosis is
not caused by factors outside of these cells but is a
characteristic of the transgenic thymocytes.
Fas–Fas ligand (FasL)-independent apoptosis of
thymocytes in Vpr-Tg mice
To examine whether the Fas–FasL system is involved
in the Vpr-induced thymocyte apoptosis, we produced
gld/gld Vpr-Tg mice by crossing Vpr-Tg mice with gld
mice. Since gld mice have a point mutation in the fasL
ene, Fas-mediated apoptosis would not occur in those
ice (Takahashi et al., 1994). However, thymic atrophy
as still observed in gld/gld Vpr-Tg mice as observed in
pr-Tg mice (data not shown). When thymocytes were
tained with Annexin V, an increase of apoptotic cells
as also observed in gld/gld Vpr-Tg mice as in Vpr-Tg
ice (Fig. 8). These results indicate that the FasL is not
equired for the apoptosis induced by Vpr.
xpression of apoptosis-related genes in Vpr-Tg mice
To know the mechanisms of T lymphocyte apoptosis in
pr-Tg mice, expression of the apoptosis-related genes
ncluding fas, caspase-1, bcl-2, bcl-x, and bax was exam-
ned by Northern blot hybridization analysis. As shown in
ig. 9A, the expression levels of bcl-x and fas in vpr-
omozygous thymocytes were below half of those seen
n non-Tg mice, while those of bax, caspase-1, and bcl-2
ncreased. Taken together, these results suggest that the
as-mediated pathway is not involved in the induction of
hymocyte apoptosis by Vpr, but down-regulation of the
xpression of bcl-x and up-regulation of bax and
aspase-1 may participate in the processes.
Moreover, since previous reports suggested that Vpr
ay mimic functional aspects of GCs and induce
poptosis (Ayyavoo et al., 1997), we examined the ex-
ression of these apoptosis-related genes in the thymus
f dexamethasone (DEX)-treated non-Tg mice to com-
are with that observed in Vpr-Tg thymus. After 24 h of
EX treatment, the expression levels of bax, caspase-1,
nd bcl-2 increased and those of bcl-x and fas de-
reased in those apoptotic cells (Fig. 9B). Thus, DEX
nduced changes in the expression patterns of apopto-
is-related genes similar to those found in Vpr-Tg mice.
DISCUSSION
CD41 T cell depletion is a major problem in AIDS. So
ar, various mechanisms have been proposed for the
epletion of T cells in HIV-1-infected people, such as
epletion by direct cytotoxic activity or syncytium forma-
ion, cellular immune reaction or antibody-dependent
ellular cytotoxicity against HIV-infected T cells, apopto-
is induced by cross-linking of the CD4 molecules by
p120, Nef-induced CD4 down-regulation and thymocyte
d
o
187T CELL APOPTOSIS IN MICE TRANSGENIC FOR HIV-1 vprdepletion, Tat-dependent induction of T cell apoptosis,
and increased sensitivity to TNF-a or Fas of the infected
T cells (Banda et al., 1992; Brady et al., 1993; Kobayashi
et al., 1990; O’Brien and Pomerantz, 1997; Skowronski et
al., 1993; Westendorp et al., 1995). However, concrete
evidence for the involvement of these mechanisms in the
reduction of T cells in vivo has not been presented yet.
Here, we have first shown that Vpr can induce T cell
apoptosis and causes T cell depletion in the peripheral
blood as well as in the lymphatic organs of a living
animal. The T cell number in the peripheral blood of
homozygous Vpr-Tg mice was reduced to only 5% of that
in normal mice, a symptom very similar to that observed
in AIDS patients. These observations suggest that Vpr
may also participate in the T cell depletion in HIV-1-
infected people together with other mechanisms men-
tioned above by causing apoptosis of these cells. Con-
sistent with this notion, the importance of apoptotic cell
death in the T cell depletion during AIDS progression
was emphasized repeatedly (Groux et al., 1992; Meyaard
et al., 1992).
Apoptotic cell death of T lymphocytes in Vpr-Tg mice
was shown by the condensation of the chromosomal
DNA, Annexin V staining of phosphatidylserine of the
FIG. 6. Histopathological analysis of the thymus. (A and C) Non-Tg
staining. Medulla, central area with light staining; cortex, outer area o
Detection of apoptotic cells by TUNEL method. Apoptotic cells were sta
in the Vpr-Tg mouse thymus. Original magnification 350.plasma membrane, and DNA lesions detected by TUNEL
methods. Moreover, Tg thymocytes showed shorter half-life in culture, suggesting increased apoptosis of these
cells. The augmentation of T cell apoptosis was ob-
served in the thymus, lymph nodes, and PBL. Since the
expression levels in peripheral lymphocytes were rela-
tively low, it was suggested that low levels of Vpr are
enough to induce apoptosis or the effects of the high
level expression in thymocytes appear later in the pe-
riphery. The reduction of T cells in the periphery is
considered to reflect both reduced supply of T cells from
the thymus and enhanced apoptosis in the periphery.
CD41CD82 cells were most severely affected in the
thymus and both CD41CD82 and CD42CD81 T cells
ecreased in peripheral lymphatic organs. The reduction
f CD42CD81 T cells may reflect the tissue specificity of
the CD4 enhancer/promoter, which lacks the silencer
element, allowing expression in both CD4- and CD8-
positive cells (Sawada et al., 1994). Thus, it was clearly
shown that HIV-1 Vpr causes apoptosis of T lympho-
cytes. The increase of the S-phase population in Tg
thymocytes may reflect enhanced thymocyte proliferation
to compensate for the depletion. Although T cell deple-
tion was also observed in HIV-1 Nef-Tg mice, this is
mainly due to the defect in T cell development and cell
surface CD4 down-regulation and not by T cell apoptosis
, (B and D) homozygous Vpr-Tg mouse. (A and B) Hematoxylin–eosin
lla. Note the marked reduction of thymocytes in the cortex. (C and D)
rown in their nuclei. Note that the number of apoptotic cells increasedmouse
f medu
ined b(Brady et al., 1993; Skowronski et al., 1993).
Then, we investigated the mechanisms of T cell
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188 YASUDA ET AL.apoptosis in Vpr-Tg mice. We found that Vpr-induced
apoptosis is not dependent on the Fas–FasL system,
since the thymus of gld/gld Vpr-Tg mice was similarly
involuted due to the enhancement of thymocyte apopto-
sis compared to wild-type Vpr-Tg mice. Instead, we no-
ticed that the expression of several apoptosis-related
genes was altered in the thymus of Vpr-Tg mice; the
expression of bax, which is known to facilitate apoptosis
(Oltvai et al., 1993), was increased, while bcl-x expres-
sion, which suppresses apoptosis (Boise et al., 1993),
was down-regulated. Moreover, the expression of an
apoptosis-related protease, Caspase-1, was elevated in
those mice. Thus, these observations suggest that the
altered expression of the bcl-2 family and the caspases
is involved in the T cell apoptosis in Vpr-Tg mice. Al-
though bcl-2, which is thought to be antiapoptotic, in-
reased in both Vpr-Tg and GC-treated mice, this in-
rease seems not to be enough to prevent the apoptosis.
Interestingly, similar changes in bcl-2 family expres-
ion and caspase expression were observed in the thy-
ocytes when mice were treated with GC, suggesting
FIG. 7. Reduced viability of thymocytes from Vpr-Tg mouse in culture.
Thymocytes from non-Tg and homozygous Vpr-Tg mice were cultured
and surviving cells were monitored at the indicated times using trypan
blue exclusion assay (A) and MTT assay (B). These results are repre-
sentative of three independent experiments.hat Vpr mimicked some functional aspects of GC. These
bservations are consistent with the recent report by
wAyyavoo et al. that Vpr could interact with GR and mimic
GC action in vitro (Ayyavoo et al., 1997). Kino et al. also
reported that Vpr enhances the activity of GC by direct
interaction with the GR and general transcription factors
(Kino et al., 1999). Thus, Vpr may mimic GC effects on
apoptosis through induction of IkB transcription (Auphan
t al., 1995; Ayyavoo et al., 1997; Scheinman et al., 1995)
r by directly interfering with NFkB action (De Bosscher
et al., 1997).
Although Stewart et al. suggested that Vpr causes
apoptosis through arrest of the cell cycle at the G2 phase
using Vpr-transfected HeLa cells, we did not detect any
cell cycle arrest in thymocytes of the Vpr-Tg mice (Stew-
art et al., 1997). The reason for this discrepancy is not
clear completely, but it seems likely that the cell type
difference affects the results, since so far G2 arrest was
observed only in HeLa or Jurkat cells, although we can-
not exclude the possibility completely that species dif-
ference affected the results. In this connection, Nishino
et al. reported that the G2 arrest was not induced in
NIH3T3 cells (Nishino et al., 1997). In either case, it was
shown that there is no correlation between the ability of
Vpr to stimulate GC response and its cell cycle-blocking
activity using Vpr mutants (Mahalingam et al., 1997; Kino
et al., 1999; Sherman et al., 2000).
Thymic atrophy and T cell apoptosis are also observed
in AIDS patients (Grody et al., 1985; Joshi et al., 1986;
Reichert et al., 1983). It is known that HIV infection of the
FIG. 8. Vpr-induced apoptosis of thymocytes in gld/gld mutant mice.
hymocytes from Vpr-Tg or non-Tg mice with or without the gld null
utation were stained with Annexin V and PI. Note that apoptotic cells
ere increased in both gld/1 and gld/gld mice. These results are
representative of two independent experiments.
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189T CELL APOPTOSIS IN MICE TRANSGENIC FOR HIV-1 vprthymus is one of the important pathogenic factors for the
development of AIDS in the case of mother–infant infec-
tion (Kourtis et al., 1996). When the thymus is infected
with HIV, T cells are immediately depleted in both the
thymus and the peripheral lymphatic organs, causing
rapid disease progression and serious symptoms. It was
suggested that Vpr plays an important role in the infec-
tion and replication of mother–infant isolates that are
involved in perinatal transmission, because an intact vpr
gene was maintained following mother-to-infant trans-
mission (Yedavalli et al., 1998) and Vpr mutations at the
C-terminus clustered in a long-term nonprogressing
mother and child pair (Wang et al., 1996). These obser-
vations are consistent with our notion that Vpr may play
an important role in the pathogenesis of AIDS by induc-
ing apoptosis in T cells.
Vpr-Tg mice provide a new animal model to study the
FIG. 9. Augmentation of apoptosis-related gene expression in the
thymus. The expression of apoptosis-related genes in thymocytes from
Vpr-Tg (A) and DEX-treated non-Tg (B) mice was analyzed by Northern
blot hybridization. The expression levels were normalized to those of
b-actin and the values relative to those in untreated non-Tg mice are
indicated. The data represent the averages and the SD of four inde-
pendent experiments. Student’s t test was used for statistical evalua-
ion of the results. *P , 0.05; **P , 0.01.mechanisms of T cell depletion caused by HIV infection.
These Tg mice should also be useful to examine possi-ble therapeutics for AIDS targeted to Vpr. We are now
analyzing the mechanisms of the gene expression mod-
ification by Vpr.
MATERIALS AND METHODS
Transgene construction
The HIV-1 NL4-3 vpr open reading frame was amplified
from the HIV-1 infectious clone, pNL4-3-2 (Adachi et al.,
1986), by polymerase chain reaction with oligo 1 (sense
orientation, 59-AAA TGA TAT CGG AAA GAT GGA ACA
AGC CC-39) and oligo 2 (antisense orientation, 59-TGC
AGA TAT CTA GTC TAG GAT CTA CTG GC-39) with the
EcoRV site (underlined) at the 59 end. The EcoRV frag-
ment containing the vpr gene was isolated (0.3 kb) and
was inserted into the EcoRV site of pCDGH, which con-
sisted of the mouse CD4 enhancer/promoter and a hu-
man growth hormone gene with its poly(A)-addition sig-
nal but was devoid of the initiation codon, to generate
pCVG (see Fig. 1). For microinjection, the XhoI–NotI frag-
ment of this plasmid (3.3 kb) was used.
Production of HIV-1 Vpr-Tg mice
The XhoI–NotI fragment was recovered from a 0.8%
agarose gel using GeneClean II (Bio 101, Vista, CA) and
was dissolved in 10 mM Tris–HCl/0.25 mM EDTA (pH 7.5)
at a concentration of 2.7 mg/ml (500 copies/pl) and mi-
roinjected into the male pronuclei of fertilized mouse
ggs (C3H/HeN) (Iwakura et al., 1992). The transgene
as detected by dot-blot hybridization using DNA pre-
ared from mouse tails (Hogan et al., 1994). Mice were
ept under specific pathogen-free conditions in an envi-
onmentally controlled clean room at the Laboratory An-
mal Research Center, Institute of Medical Science, Uni-
ersity of Tokyo. All equipment and supplies, including
ages, water bottles, wooden chips, and food pellets,
ere sterilized. The experiments were conducted ac-
ording to the institutional ethical and safety guidelines
or animal experiments and safety guideline for gene
anipulation experiments.
orthern blot hybridization
Total cellular RNA was prepared by the acid gua-
idium thiocyanate–phenol–chloroform method (Chom-
zynski and Sacchi, 1987). Messenger RNA was purified
rom total RNA by using the QuickPrep Micro mRNA
urification kit (Pharmacia Biotech, Piscataway, NJ) and
as electrophoresed on a 1.2% agarose gel containing
ormaldehyde and blotted onto the Gene Screen Plus
embrane (Du Pont NEN, Boston, MA). After UV cross-
inking, the membrane was hybridized with 32P-labeled
DNA probes prepared using the Multiprime labeling sys-
tem (Amersham, Boston, MA) at 42°C overnight. The
autoradiograms were developed and the radioactivity of
each band was quantified by a BAS 2000 Bio-Image
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190 YASUDA ET AL.analyzer (Fuji Photo Film, Tokyo, Japan). An EcoRV–NotI
(2.1 kb) fragment from pCVG was used as a probe to
detect vpr mRNA. Murine fas cDNA (Watanabe-Fukunaga
et al., 1992) was obtained from Dr. Sigekazu Nagata
(Osaka Bioscience Institute, Japan) and the EcoRI frag-
ment (1.8 kb) was used as probe. Murine caspase-1
cDNA (Miura et al., 1993) was obtained from Dr. Mas-
ayuki Miura (Osaka University, Japan) and murine bcl-2
(Negrini et al., 1987), bcl-x (Gonzalez-Garcia et al., 1994),
and bax (Oltvai et al., 1993) cDNAs were obtained from
Dr. Yoshihide Tsujimoto (Osaka University, Japan).
Western blotting
Tissues were lysed in a buffer containing 25 mM
Tris–HCl (pH 8.0), 50 mM NaCl, 1% Triton X-100, 1%
deoxycholate, and 0.2 mM PMSF. The cell lysates were
electrophoresed on a SDS–polyacrylamide gel (13%) and
blotted onto a polyvinylidene difluoride membrane filter
(Millipore, Bedford, MA). The filter was incubated with
anti-Vpr antibody (Y. Aida et al., in preparation) and then
with horseradish peroxidase-conjugated protein A. Then,
the products were detected with enhanced chemilumi-
nescence (ECL plus) detection reagents (Amersham).
Flow cytometric analysis
The antibodies used were a phycoerythrin (PE)-conju-
gated rat monoclonal antibody against mouse CD45R/
B220 (RA3-6B2), a fluorescein isothiocyanate (FITC)-con-
jugated hamster monoclonal antibody against mouse
CD3-e (145-2C11), a PE-conjugated rat monoclonal anti-
body against mouse CD4 (L3T4: RM4-5), and a FITC-
conjugated rat monoclonal antibody against mouse
CD8a (Ly-2: 53-6.7) (PharMingen, San Diego, CA). Single-
cell suspensions were obtained from the thymus, spleen,
lymph nodes, and PBL, and incubated with the antibod-
ies on ice for 30 min. After washing, cells were analyzed
by a FACScan cell analyzer with Lysis II software (Bec-
ton–Dickinson, Franklin Lakes, NJ).
Cell cycle analysis
Thymocytes from transgenic mice were fixed in 0.3%
paraformaldehyde–PBS for 1 h on ice, permeabilized by
0.2% Triton X-100–PBS on ice for 15 min, and then incu-
bated in FACS solution (Hanks’ solution containing 0.03%
NaHCO3, 0.01% NaN3, 2% FCS) containing 40 mg/ml PI
and 40 mg/ml RNase A. Stained cells were analyzed by a
ACScan cell analyzer with CellFIT software (Becton–
ickinson).
etection of apoptotic cells by Annexin V
Apoptotic cells were detected with the Apoptosis De-
ection Kit (MBL, Nagoya, Japan). Briefly, lymphocytes
rom transgenic mice were stained with Annexin V–FITCnd PI, and cells were analyzed by using a FACScan cell
nalyzer with Lysis II software.
istological examination
All tissues were fixed in 10% neutralized formalin,
mbedded in paraffin, and sectioned at 4 mm. Sections
were stained with hematoxylin and eosin for histological
examination. Apoptosis was detected using the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP–
digoxigenin nick-end labeling method (Gavrieli et al.,
1992). In brief, paraffin sections were deparaffinized and
treated with proteinase K, and the 39-OH ends of frag-
mented chromosomal DNA were labeled with digoxige-
nin-labeled nucleotides by TdT (Apoptag; Oncor, Gaith-
ersburg, MD). Incorporated digoxigenin was detected by
anti-digoxigenin Ab–peroxidase complex. Samples di-
gested for 30 min with 2 mg/ml DNase I were used as a
ositive control and those processed without TdT as a
egative control.
ell viability test of thymocytes
Thymocytes from non-Tg and Vpr-Tg mice were iso-
ated and suspended in RPMI 1640 supplemented with
0% FCS. Then, the viability in culture was estimated by
rypan blue exclusion test and MTT assay (Mosmann,
983). Briefly, the MTT assay was carried out as follows:
ells were seeded in 96-well flat-bottomed plates at 5 3
05 cells/100 ml, and after culture at 37°C under 5% CO2
atmosphere for an appropriate period, 10 ml of 5 mg/ml
MTT was added to each well and further incubated for
4 h. Then, cells were lysed by adding 100 ml of 20% SDS,
and the optical density of each well was measured at
570 nm using a microplate reader (Corona, MTP-120,
Ibaraki, Japan).
Dexamethasone treatment
DEX (Sigma, St. Louis, MO) was dissolved in sterile
phosphate-buffered saline and injected intraperitoneally
at 5 mg/g body weight into the mice. At 24 h after
njection, mice were sacrificed and the thymus was re-
oved. All samples were frozen in liquid nitrogen and
tored at 280°C for RNA extraction.
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